SLC17A7 – Schizophrenia

The association between SLC17A7 and schizophrenia has been explored through multiple genetic studies. In a resequencing study of the VGLUT1 gene, eight rare, patient‐specific variants were detected in 16 of 376 schizophrenic patients (PMID:19720501), with no such variants observed in the 368 control subjects. This rare variant enrichment supports a role for SLC17A7 in disease predisposition.

An independent study assessed common polymorphisms in an expanded cohort of 805 schizophrenia patients and identified a nominal association of the SLC17A7 rs62126236*T allele with reduced negative symptom severity (PMID:36980845). Although no overall allele frequency differences were detected between patients and controls, this observation further hints at the gene’s involvement in clinical heterogeneity.

Functional assessment studies provide robust biological context for these genetic findings. Multiple experiments, including investigations in rodent models, have demonstrated that VGLUT1 (encoded by SLC17A7) is critically involved in glutamatergic neurotransmission. For instance, VGLUT1 knockout and heterozygous mouse models showed impaired hippocampal long-term potentiation and deficits in spatial reversal learning, underscoring the transporter’s role in synaptic plasticity (PMID:19574394). Additional studies have elucidated complex trafficking mechanisms of VGLUT1, supporting its functional specificity in synaptic compartments (PMID:23804088).

While one study reported no significant differences in common variant frequencies between schizophrenia patients and controls (PMID:19720501), the discovery of patient-specific rare variants and supportive functional data lends moderate credence to the gene–disease association. No familial segregation data have been reported; hence, evidence remains primarily based on case–control observations and functional validation.

The integration of genetic and experimental findings suggests that SLC17A7 contributes to schizophrenia pathogenesis, likely through its role in glutamate packaging and synaptic function. Further replication and more extensive studies may provide additional insight, but current data offer a valuable lead for diagnostic decision‑making and potential therapeutic exploration.

Key Take‑home: Although the overall genetic signal is moderate, converging functional evidence supports considering SLC17A7 as a relevant factor in schizophrenia, justifying its inclusion in future diagnostic and research panels.

References

• Schizophrenia research • 2009 • Resequencing and association study of vesicular glutamate transporter 1 gene (VGLUT1) with schizophrenia PMID:19720501
• Genes • 2023 • The Role of Glutamatergic Gene Polymorphisms in the Clinical Phenotypes of Schizophrenia PMID:36980845
• Journal of neurochemistry • 2006 • Developmentally-regulated expression of tissue-specific splice variant of rat vesicular glutamate transporter 1 in retina and pineal gland PMID:16987242
• Cerebral cortex • 2010 • Vesicular glutamate transporter VGLUT1 has a role in hippocampal long-term potentiation and spatial reversal learning PMID:19574394
• The Journal of neuroscience • 2013 • Multiple dileucine-like motifs direct VGLUT1 trafficking PMID:23804088
• PloS one • 2014 • Protein interactions of the vesicular glutamate transporter VGLUT1 PMID:25334008
• Biochimica et biophysica acta. Biomembranes • 2017 • Function and expression of a splicing variant of vesicular glutamate transporter 1 PMID:28188742

Evidence Based Scoring (AI generated)